Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
PLoS One ; 12(1): e0170359, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28129346

RESUMO

The Dengue Duo Rapid Diagnostic Test (SD Dengue RDT) has good specificity and sensitivity for dengue diagnosis in rural tropical areas. In a previous study, using four control sera, we demonstrated that that the diagnostic accuracy of these RDTs remains stable after long-term storage at high temperatures. We extended this study by testing sera from 119 febrile patients collected between July-November 2012 at Salavan Provincial Hospital (southern Laos) with RDTs stored for 6 months at 4°C, 35° and in a hut (miniature traditional house) at Lao ambient temperatures. The dengue NS1 antigen results from RDTs stored at 35°C and in the hut demonstrated 100% agreement with those stored at 4°C. However, lower positive percent agreements, with broad 95%CI, were observed for the tests: IgM, 60% (14.7-94.7) and 40% (5.3-85.3) for RDTs store at 35°C and in the hut, compared to those stored at 4°C, respectively. This study strenghtens the evidence of the robustness of the NS1 antigen detection RDT for the diagnosis of dengue after storage at tropical temperatures.


Assuntos
Vírus da Dengue/isolamento & purificação , Dengue/diagnóstico , Testes Diagnósticos de Rotina/normas , Kit de Reagentes para Diagnóstico/normas , Anticorpos Antivirais/química , Anticorpos Antivirais/imunologia , Dengue/virologia , Vírus da Dengue/patogenicidade , Feminino , Temperatura Alta , Humanos , Laos , Masculino , Clima Tropical , Proteínas não Estruturais Virais/imunologia
3.
Lancet Glob Health ; 1(1): e46-54, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24748368

RESUMO

BACKGROUND: Because of reductions in the incidence of Plasmodium falciparum malaria in Laos, identification of the causes of fever in people without malaria, and discussion of the best empirical treatment options, are urgently needed. We aimed to identify the causes of non-malarial acute fever in patients in rural Laos. METHODS: For this prospective study, we recruited 1938 febrile patients, between May, 2008, and December, 2010, at Luang Namtha provincial hospital in northwest Laos (n=1390), and between September, 2008, and December, 2010, at Salavan provincial hospital in southern Laos (n=548). Eligible participants were aged 5-49 years with fever (≥38°C) lasting 8 days or less and were eligible for malaria testing by national guidelines. FINDINGS: With conservative definitions of cause, we assigned 799 (41%) patients a diagnosis. With exclusion of influenza, the top five diagnoses when only one aetiological agent per patient was identified were dengue (156 [8%] of 1927 patients), scrub typhus (122 [7%] of 1871), Japanese encephalitis virus (112 [6%] of 1924), leptospirosis (109 [6%] of 1934), and bacteraemia (43 [2%] of 1938). 115 (32%) of 358 patients at Luang Namtha hospital tested influenza PCR-positive between June and December, 2010, of which influenza B was the most frequently detected strain (n=121 [87%]). Disease frequency differed significantly between the two sites: Japanese encephalitis virus infection (p=0·04), typhoid (p=0·006), and leptospirosis (p=0·001) were more common at Luang Namtha, whereas dengue and malaria were more common at Salavan (all p<0·0001). With use of evidence from southeast Asia when possible, we estimated that azithromycin, doxycycline, ceftriaxone, and ofloxacin would have had significant efficacy for 258 (13%), 240 (12%), 154 (8%), and 41 (2%) of patients, respectively. INTERPRETATION: Our findings suggest that a wide range of treatable or preventable pathogens are implicated in non-malarial febrile illness in Laos. Empirical treatment with doxycycline for patients with undifferentiated fever and negative rapid diagnostic tests for malaria and dengue could be an appropriate strategy for rural health workers in Laos. FUNDING: Wellcome Trust, WHO-Western Pacific Region, Foundation for Innovative New Diagnostics, US Centers for Disease Control and Prevention


Assuntos
Doenças Transmissíveis/complicações , Febre/etiologia , Doença Aguda , Adolescente , Adulto , Criança , Pré-Escolar , Doenças Transmissíveis/epidemiologia , Feminino , Febre/epidemiologia , Humanos , Laos/epidemiologia , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Estações do Ano , Adulto Jovem
4.
Am J Trop Med Hyg ; 83(6): 1221-9, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21118925

RESUMO

We conducted an open, randomized clinical trial of oral dihydroartemisinin-piperaquine (DP) versus artesunate-mefloquine (AM) in 300 patients in Laos with uncomplicated Plasmodium falciparum malaria as part of a multicentre study in Asia. Survival analysis and adjustment for re-infection showed that the 63-day cure rates (95% confidence interval [CI]) were 100% for AM and 99.5% (96.4-99.8%) for DP. The 63-day cure rates per protocol were 99% (97 of 98) for AM and 99.5% (196 of 197) for DP (P = 0.55). The difference (AM minus DP) in cure rates (95% CI) was -0.5% (-5.1 to 2.0%), which is within the 5% non-inferiority margin. The median fever and parasite clearance times were also similar for AM and DP. The proportion of patients with at least one recorded potential adverse event was significantly higher in the AM group (38 of 87, 44%) than in the DP group (57 of 182, 31%) (relative risk = 0.6, 95% CI = 0.4-0.9; P = 0.04). Dihydroartemisinin-piperaquine is not inferior to AM in the treatment of uncomplicated P. falciparum malaria in Laos and is associated with fewer adverse effects. The results of this study were similar to those of the larger multicentre study.


Assuntos
Artemisininas/administração & dosagem , Malária Falciparum/tratamento farmacológico , Mefloquina/administração & dosagem , Quinolinas/administração & dosagem , Adolescente , Adulto , Antimaláricos/administração & dosagem , Antimaláricos/efeitos adversos , Antimaláricos/uso terapêutico , Artemisininas/efeitos adversos , Artemisininas/uso terapêutico , Artesunato , Criança , Pré-Escolar , Quimioterapia Combinada , Feminino , Humanos , Laos/epidemiologia , Malária Falciparum/epidemiologia , Masculino , Mefloquina/efeitos adversos , Mefloquina/uso terapêutico , Quinolinas/efeitos adversos , Quinolinas/uso terapêutico , Adulto Jovem
5.
BMC Public Health ; 7: 193, 2007 Aug 04.
Artigo em Inglês | MEDLINE | ID: mdl-17683576

RESUMO

BACKGROUND: In 2002 and 2003 there were large outbreaks of measles in many provinces of Laos, including in Vientiane. We therefore conducted a study to determine risk factors associated with measles amongst children admitted at Mahosot Hospital, Vientiane. METHODS: A retrospective case-control study was conducted in 50 children with clinical measles who were matched by age and sex with 50 healthy children (who had never had a febrile rash) living in the same villages as the cases. RESULTS: The proportion of children with complete immunizations was significantly lower in the group with clinical measles compared to the controls [13/50 (26%) vs 34/50 (68%), P < 0.001). The percentage of children who had received measles vaccine at 9-23 months of age was significantly lower in the group with clinical measles compared to the healthy controls [12/50 (24%) vs 24/50 (48%), P = 0.01). The family educational and socio-economic status did not differ significantly (P > 0.05) between cases and controls. CONCLUSION: These results emphasize the importance of intensification of measles immunization coverage in Laos. The strengthening of campaigns with large, widespread high second dose coverage is likely to be a key measure to prevent further measles outbreaks in Laos (192 words).


Assuntos
Surtos de Doenças , Sarampo/epidemiologia , Adulto , Estudos de Casos e Controles , Pré-Escolar , Surtos de Doenças/prevenção & controle , Feminino , Hospitalização/estatística & dados numéricos , Humanos , Programas de Imunização , Lactente , Laos/epidemiologia , Masculino , Sarampo/prevenção & controle , Vacina contra Sarampo/administração & dosagem , Vacina contra Sarampo/provisão & distribuição , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA